Promoter group declares no encumbrance on shares for FY26

Ownership Changes View source PDF Explain this filing

DIVISLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.9%Reaction day

₹6752.00

prior close

₹6803.50

announcement price

In-mkt

timing

Nifty 100market+0.6%+1.2% vs market

Pharmaceuticals peers, median of 164sector-0.5%+2.4% vs sector

On the reaction day the stock moved 1.2 pts more than Nifty 100 and 2.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

+0.1

15m

-0.1

30m

+0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.9+0.6+1.2-0.5+2.4

Next day

+0.1+0.4-0.3-0.7+0.8

-0.2-1.7+1.4-1.7+1.5

+1.0-1.2+2.3-1.3+2.3

+1.2-0.2+1.4-0.5+1.7

+2.7-0.2+2.9+0.2+2.4

+8.2-0.7+8.9+0.4+7.8

15d

+10.2-0.8+11.0-1.4+11.6

+23.7+1.8+21.9-1.7+25.3

+37.7-1.6+39.3+1.2+36.5

+41.1-5.6+46.7+0.4+40.7

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Dr Murali K Divi, promoter and Managing Director of Divi's Laboratories, has filed a declaration under SEBI takeover regulations confirming that the promoter group, which collectively holds 51.82 percent of the company, did not create any encumbrance or pledge on their shares during the financial year ended 31 March 2026. This is a routine annual compliance filing under Regulation 31(4).

Likely market impact

Positive signal. Confirms promoter stake of 51.82% remains free of pledges, meaning no margin call risk. Routine disclosure, no material business impact.